Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Licogliflozin







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Licogliflozin
Legal status
Legal status
  • Investigational
Identifiers

  • (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

CAS Number
PubChem CID
Chemical and physical data
FormulaC23H28O7
Molar mass416.470 g·mol−1
3D model (JSmol)

  • CCC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4

  • InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1

  • Key:XFJAMQQAAMJFGB-ZQGJOIPISA-N

Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity,[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis.[2][3]

References[edit]

  1. ^ Zaki AM, Abo-Elnour DE, Abdalla YE, Hassan RY, Salama MK, Elboraay T, et al. (November 2022). "Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials". Diabetes & Metabolic Syndrome. 16 (11): 102657. doi:10.1016/j.dsx.2022.102657. PMID 36335885.
  • ^ Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, et al. (November 2021). "Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial". Diabetes, Obesity & Metabolism. 23 (11): 2595–2599. doi:10.1111/dom.14495. PMID 34263971.
  • ^ Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, et al. (July 2022). "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study". Nature Medicine. 28 (7): 1432–1438. doi:10.1038/s41591-022-01861-9. PMC 10061496. PMID 35725922.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Licogliflozin&oldid=1233320060"
    Categories: 
    ●SGLT2 inhibitors
     ●Glucosides
     Hidden categories: 
    ●Articles with short description
     ●Short description with empty Wikidata description
     ●Drugs with non-standard legal status
     ●Infobox drug articles with non-default infobox title
     ●Articles without EBI source
     ●Chemical pages without ChemSpiderID
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without UNII source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 8 July 2024, at 13:16 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki